Myelodysplastic syndrome
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Who can joinAdults
Age18+ years
Kind of studyPhase 3: compared with usual treatment
What it testsA medicine
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Where to go
8 hospitals in India taking patients for this trial.
Heamto Oncology Clinic Ahmedabad Pvt. Ltd.Ahmedabad, GujaratDirections ↗
Apollo Hospital International LtdAhmedabad, GujaratDirections ↗
All India Institute of Medical ScienceNew Delhi, National Capital Territory of DelhiDirections ↗
Christian Medical College, LudhiananaLudhiana, PunjabDirections ↗
Christian Medical CollegeVellore, Tamil NaduDirections ↗
NRS Medical College and HospitalKolkata, West BengalDirections ↗
Tata Medical Center, KolkataKolkata, West BengalDirections ↗
Medanta the MedicityGūrgaonDirections ↗
Registry summary (technical)
The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept works in reducing the need for RBC transfusions over longer periods of time or in adults with high transfusion needs. The study will also check on how safe elritercept is and how well it is tolerated.
Sponsor: Takeda
NCT06499285 on ClinicalTrials.gov
Last updated on the registry 8 Oct 2026 · read by us 20 Oct 2026